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Basal-like breast cancer (BBC) is a subtype of breast cancer
with poor prognosis1–3. Inherited mutations of BRCA1, a
cancer susceptibility gene involved in double-strand DNA
break (DSB) repair, lead to breast cancers that are nearly
always of the BBC subtype3–5; however, the precise molecular
lesions and oncogenic consequences of BRCA1 dysfunction
are poorly understood. Here we show that heterozygous
inactivation of the tumor suppressor gene Pten leads to the
formation of basal-like mammary tumors in mice, and that loss
of PTEN expression is significantly associated with the BBC
subtype in human sporadic and BRCA1-associated hereditary
breast cancers. In addition, we identify frequent gross PTEN
mutations, involving intragenic chromosome breaks, inversions,
deletions and micro copy number aberrations, specifically in
BRCA1-deficient tumors. These data provide an example of
a specific and recurrent oncogenic consequence of BRCA1-
dependent dysfunction in DNA repair and provide insight into
the pathogenesis of BBC with therapeutic implications. These
findings also argue that obtaining an accurate census of genes
mutated in cancer will require a systematic examination for
gross gene rearrangements, particularly in tumors with
deficient DSB repair.
Advances in methodologies for high-throughput DNA sequencing and
copy number analysis have hastened the global cataloguing of genetic
abnormalities in cancer (for example, see refs. 6–8). Although such
studies have identified classical coding mutations and large amplifica-
tions and deletions in known and putative oncogenes and tumor
suppressors, some types of genetic change, such as chromosome
breaks, gene translocations and microduplications or microdeletions,
are difficult to detect. Indeed, recurrent fusions between TMPRSS2
and ETS family transcription factor genes have been identified in
prostate carcinoma by a systems biology approach9, and they suggest
that oncogenic gene rearrangements may be common in epithelial
neoplasia. Global gene expression profiling studies of breast carcinoma
have delineated several molecular subtypes that have distinct patho-
logical and clinical characteristics1–5. Of these, basal-like breast cancer
(BBC) comprises 10–20% of all breast cancer and is one of the
subtypes with the worst prognosis2–5. The term BBC was coined
because these tumors express cytokeratin markers typical of basally
oriented epithelial cells of the normal mammary gland, such as CK5,
CK14 and CK17 (refs. 1,3,5). In addition to having characteristic
cytokeratin expression, BBCs are highly proliferative, poorly differ-
entiated and genomically unstable, and they pose clinical challenges
because they rarely express the three most common therapeutically
targeted ‘Achilles’ heels’ of breast cancer: the estrogen receptor (ER),
progesterone receptor and HER2 receptor (refs. 1,3,5,7).
Intriguingly, breast tumors initiated by an inherited mutation of
BRCA1 are nearly always basal-like3,5. BRCA1 dysfunction is thought
to be tumorigenic primarily owing to defective BRCA1-dependent
DSB repair, which precipitates an accumulation of secondary muta-
tions10; however, only general genomic patterns at relatively low
resolution have been described (reviewed in ref. 5). Despite these
advances in delineating BBC, the molecular lesions and oncogenic
signaling pathways that drive BBC and the precise oncogenic con-
sequences of BRCA1-mediated basal-like tumorigenesis are incomple-
tely known. The phosphatidylinositol 3-kinase (PI3K) pathway is a
potent oncogenic signaling cascade that promotes cell transformation,
proliferation, migration, angiogenesis and genomic instability; inhibits
apoptosis; maintains stem cell compartments; and is associated with
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poor prognosis in carcinoma11–14. PTEN is the crucial tumor
suppressor in this pathway because it catalyzes the precise opposite
reaction to PI3K, thereby inhibiting downstream signaling12. In
breast cancer, documented coding mutations of PTEN are rare
(o5%); however, B25% of tumors have significantly diminished
amounts of PTEN protein, resulting in unrestrained signaling by
the PI3K pathway15.
While reviewing breast cancer subtypes in mouse models, we noted
that all 13 mammary tumors derived from 12 mice with heterozygous
inactivation of one Pten allele16 showed basal-like characteristics
(positive staining for CK5, CK6 or CK14 (hereafter CK5/6/14) by
immunohistochemistry (IHC); Fig. 1 and Supplementary Table 1
online). To investigate the role of PTEN in human BBC, we therefore
characterized PTEN and CK5/14 protein expression by IHC in non-
hereditary breast tumors from 297 individuals (Fig. 2a). A reduction
in PTEN protein immunostaining (PTENIHC-loss) of tumor cells as
compared with adjacent non-neoplastic cells was observed significantly
more frequently in CK5/14-positive BBC than in CK5/14-negative
non-BBC (54.3 versus 13.4%, respectively; P ¼ 4  10–9; Fig. 2b and
Supplementary Table 2 online). Because both the BBC phenotype1,3,5
and reduced PTEN15 have been associated with lack of ER expression,
we tested the relationship between PTEN and basal-like status in the
ER-negative subset and found that it remained significant (56.3 versus
29.1%; P ¼ 0.0122; Fig. 2b and Supplementary Table 2 online).
Loss of PTEN thus defines a significant subset of non-hereditary
BBC (NHBBC).
Given that nearly all BRCA1-associated hereditary breast cancers are
basal-like3,5,17, we next investigated PTEN expression in 34 breast tumor
biopsies from individuals with inherited BRCA1 mutations (hereditary
BBC (HBBC); Supplementary Table 3 online). Notably, 82.4%
(28/34) of tumors showed loss of PTEN by IHC (P ¼ 4  10–12;
Fig. 3a). In addition, suggestive of a genetic mechanism for PTEN
loss, 52.9% (18/34) of tumors showed a marked staining pattern;
namely, PTEN protein was completely undetectable in tumor cells
(PTENIHC-null) but strongly expressed in adjacent normal cells
(Fig. 3a–c,e). To test for an association between the PTENIHC-null
phenotype and mutation of PTEN, we screened 14 PTENIHC-null
non-hereditary breast tumors (Fig. 3d) and 8 PTENIHC-null HBBC
tumors (Fig. 3a–c) for mutations in PTEN by DNA sequencing.
Whereas half of the PTENIHC-null non-hereditary tumors had coding
mutations in PTEN, unexpectedly, no sequence alterations were found
in the HBBC samples (P ¼ 0.0154; Fig. 3f). These results, together
with the fact that the HCC-1937 BRCA1-mutant cell line is known to
have homozygous deletion of PTEN18, suggested that BRCA1-mutant
tumors may have a distinct type of PTEN genetic lesion.
To investigate this possibility, we examined two model breast
cancer cell lines, MDA-MB-436 and SUM-149, that are known to
have mutations in BRCA1 (ref. 19) and to be basal-like20. These cell
lines are ideal models because both carry the wild-type PTEN gene,
as determined by DNA sequencing, but neither expresses PTEN
protein, as assessed by protein blotting. In addition, PTEN expression
cannot be induced by treatment with demethylation agents, indicating
that PTEN silencing is not due to promoter methylation (data
not shown). Conventional tiling BAC array comparative genomic
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Pten+/– mouse mammary tumor no.
Glandular tumor compartment Metaplastic tumor compartment
Figure 1 IHC analysis of basal-like phenotype markers in Pten+/– mouse mammary tumors. (a) Representative section showing IHC staining for CK5/6, CK14
and ER in a Pten+/– mammary tumor (top) and normal breast tissue from a wild-type (Pten+/+) control mouse (bottom). Arrows indicate tumor cells; filled
arrowheads indicate non-neoplastic basal-layer epithelial cells; open arrowhead indicates non-neoplastic luminal-layer epithelial cells. Scale bars, 25 mm.
(b) CK5/6/14 IHC staining scores for 13 Pten+/– mammary tumors. The maximal score for CK5/6 or CK14 staining (Methods) is plotted for each tumor
compartment; a score of 1+ (horizontal broken line) is defined as basal-like. 0, tumor compartment present but no staining; np, respective component not
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Figure 2 Immunohistochemical analysis of PTEN and CK5/14 basal-like
phenotype markers in 297 non-hereditary human breast carcinomas.
(a) Representative PTEN and CK5/14 IHC in two non-hereditary breast
tumors. Top, a PTENIHC-positive and CK5/14-negative example; bottom, a
PTENIHC-loss and CK5/14-positive example. Arrows indicate tumor cells;
arrowheads indicate non-neoplastic cells. Asterix denotes the non-neoplastic
CK5/14-positive basal epithelial layer enclosing a portion of in situ breast
carcinoma, shown here as an example of an internal positive control.
Scale bars, 25 mm. (b) Correlation analysis between PTEN loss and the
CK5/14-positive basal-like subtype among all tumors (left) and in the
ER-negative group (right). *P ¼ 0.0122; **P ¼ 4  109.







































that both cell lines show DNA copy number loss at the PTEN locus on
chromosome 10q23.31, consistent with loss of one allele (loss of
heterozygosity; LOH).
To look for smaller genetic lesions, we used a custom-designed
high-density oligonucleotide aCGH (HD-aCGH) platform containing
1,747 probes spanning a region ofB500 kb centered on PTEN with an
average interprobe spacing of 288 bp. HD-aCGH analysis showed that
these regions of apparent PTEN LOH in fact contained highly focal,
intragenic copy number increases (CNIs) in PTEN, affecting a portion
of intron 2 (MDA-MB-436) and spanning exon 2 (SUM-149;
Fig. 4a,b). Given the role of BRCA1 in DSB repair, we considered
that the intragenic PTEN CNIs may be asso-
ciated with gross chromosomal rearrange-
ments. We therefore designed a two-color
FISH assay (Fig. 4c) and identified distinct
rearrangements of chromosome 10 that phy-
sically split the single remaining PTEN allele
in each cell line (Fig. 4d). These results were
corroborated for both cell lines by 5¢-to-3¢
exon-walking using RT-PCR, by which we
could not amplify specific PTEN transcripts
beyond exon 2 (data not shown). These data
are most consistent with a mechanism invol-
ving multiple DSBs and inappropriate repair
and reduplication of DNA segments at or
near the breakpoints.
To investigate further the association of
these types of PTEN locus structural muta-
tion (hereafter termed ‘gross’ PTEN muta-
tions; GPMs) with BRCA1 status, we
sequenced BRCA1 in three breast cancer
xenografts with identified homozygous dele-
tions of PTEN21 (Table 1, Supplementary
Table 3 and Supplementary Fig. 1 online).
One xenograft, MX-1 (also known as Bx11),
was found to have the 2795del4 BRCA1 mutation. (Although matched
normal DNA was not available, this mutation is likely to be germ
line because 2795del4 is a known BRCA1 founder mutation and
the xenograft was established from a 29-year-old individual22.) Next,
to test the relationship between BRCA1 and GPM rigorously, we
selected all breast cancer cell lines and xenografts with any type of
PTEN mutation from 31 samples that were comprehensively
annotated for BRCA1 and PTEN mutational status (all cell lines
positive for PTEN protein by protein blotting were assumed to
not have GPMs; Table 1). Among the 13 samples with any









































Figure 3 PTEN status in human BRCA1-mutant hereditary breast cancers. (a–d) PTEN IHC results for
three representative PTENIHC-null BRCA1-associated hereditary breast tumor specimens (a–c) and one
non-hereditary PTENIHC-null breast tumor with a PTEN fs108X mutation (d). Scale bars, 25 mm.
(e) Fraction of PTENIHC-loss (filled) and PTENIHC-null (open) tumors among 34 BRCA1-associated
hereditary breast tumors. (f) Analysis of PTEN nucleotide sequence mutations in PTENIHC-null


































































Figure 4 Gross PTEN mutations in BRCA1-mutant human cell lines and xenografts. (a,b) HD-aCGH analyses of two model BRCA1-mutant breast cancer cell
lines. The location of PTEN exons 1–9 on chromosome 10q23.31 are indicated by blue bars. The log2 ratios for probes localized in the PTEN gene are
plotted in red; those for all other probes are plotted in black (gaps with no probes are present in several regions that contain highly repetitive sequence
elements such as intron 2). Arrows indicate regions of focal CNI. Prominent broken horizontal lines are placed at log2 ratios of 0.3 and 0.3. (c) Two-color
FISH assay. The PTEN gene and exons are indicated in blue. Centromeric BAC probes were labeled with spectrum orange–dUTP (red); telomeric BAC probes
were labeled with spectrum green–dUTP (green). (d) FISH results for the BRCA1-mutant breast cancer cell lines in a,b. Inset, representative FISH results for
one chromosome of a normal lymphocyte metaphase spread. (e) Analysis of BRCA1 mutation (mt) and GPM among 13 breast cancer xenografts and cell
lines with any type of PTEN mutation. The basal-like status of these cell lines and xenografts is given in Table 1.







































mutations in BRCA1; by contrast, PTEN coding mutations were
specifically associated with wild-type BRCA1 (P ¼ 0.0210; Fig. 4e).
We therefore conclude that BRCA1 dysfunction is associated
with GPM.
These results were corroborated in breast tumor biopsies from
women with hereditary BRCA1 mutations. Of 17 HBBC tumors
analyzed for conventional PTEN mutations by DNA sequencing, all
had wild-type PTEN (Supplementary Table 3 online). When analyzed
on the HD-aCGH platform, however, five (71.4%) of seven
PTENIHC-null HBBC tumors had specific GPMs associated with
micro-CNIs (n ¼ 2), macro-CNI (n ¼ 1) and homozygous deletions
(n ¼ 2; Fig. 5a–e, Supplementary Table 3 and Supplementary
Fig. 1 online). Seven of these HBBC samples, in addition to one
PTENIHC-loss and three PTENIHC-positive HBBC tumors, were also
analyzed on the conventional BAC aCGH platform (data not
shown). Indicating the increased sensitivity of the HD-aCGH platform
for detecting GPMs, one homozygous deletion was difficult to discern
and both micro-CNIs were undetectable by BAC aCGH (data not
shown). In addition, beyond copy number loss consistent with
LOH, no obvious GPMs were detected in the PTENIHC-loss or
PTENIHC-positive HBBCs.
Combining our patient tumor data with our data from cell lines
and xenografts, we analyzed in total 28 BRCA1-mutant samples by
conventional BAC aCGH, custom HD-aCGH
and/or conventional DNA sequencing, and
found nine cancers (32.1%) with GPMs. We
conclude that PTEN loss is highly associated
with both NHBBC and HBBC and can result
from gene rearrangements involving DNA
DSBs, intragenic inversions or insertions,
homozygous deletions and focalized CNIs.
Because chromosomal breaks, CNIs and
small microdeletions were not detected by
conventional aCGH or DNA sequencing, we
are probably underestimating the true rate of
GPMs in HBCC. Indeed, our PTENIHC-null
data would suggest a rate of more than 50%.
In addition, we identified two NHBBC sam-
ples with homozygous deletion of PTEN and,
notably, both had hypermethylation of the
BRCA1 promoter (data not shown), suggesting
that BRCA1-dependent PTEN disruption may
also occur in some sporadic breast tumors.
Our results have important implications for
the pathogenesis and treatment of BBC and
raise significant considerations for future
mutation-cataloguing efforts in disease. The
basal-like phenotype of Pten+/– mammary
tumors and the high rate of PTEN loss in
NHBBC and HBBC imply that the PTEN
pathway is directly involved in transformation
of basal-like progenitor cells. Notably, con-
ventional sequence mutations of the TP53
tumor suppressor gene occur in 480% of
NHBBC and HBBC (reviewed in ref. 5).
Together, our results suggest that all three
tumor suppressors are inactivated in a con-
siderable proportion of BBC. Although the
spectrum of TP53 mutations seems to differ
between non-hereditary and hereditary breast
cancer23, the observed mutational profiles of
TP53 are not as specific or as markedly divergent as we have found
here for PTEN, indicating that the selective pressure and/or muta-
tional mechanism on TP53 and PTEN are likely to be distinct. Our
data are most consistent with a model of HBBC oncogenesis in which
selected stochastic coding mutation of TP53 in a basal-like breast
cancer progenitor cell precedes loss of the second BRCA1 allele, which
is known to otherwise be lethal to cells (reviewed in ref. 24), and that
the subsequent BRCA1-dependent DSB repair defect precipitates
genetic disruption of PTEN, which is then clonally selected. This
model implies that most BBCs may be addicted25 to aberrant PTEN-
PI3K pathway signaling. As a result, therapy targeted to this pathway
may be an effective way to treat and possibly to prevent some sporadic
and hereditary BBC.
Our study demonstrates an example of a specific and recurrent
oncogenic consequence of defective DSB repair in breast cancer,
and it is possible that other grossly rearranged genes also contribute
to tumor progression. Our observations in HBBC are analogous
to those in hereditary nonpolyposis colon cancer, where
microsatellite instability due to lack of mismatch repair leads
to mutation of TGFBR2 and other genes that drive tumor progres-
sion26. Our results highlight the need for high-throughput
genomic methods to screen for gross structural gene mutations
at a sub-kilobase resolution. There may be a wealth of gross mutations
Table 1 BRCA1 and PTEN status in 31 breast cancer cell lines and xenografts
Sample ID BRCA1 mutation statusa PTEN mutation status PTEN protein blot Subtypeb
HCC-1937 5382insC (fs41829X) GPM (HD) Null Basal-like
MDA-MB-436 5396+1G4A (splice donor) GPM (micro-CNI) Null Basal-like
MX-1c 2795delT (fs4999X) GPM (HD) n.d. n.a.
SUM-149 2288delT (fs4735X) GPM (micro-CNI) Null Basal-like
BT-549 WT 822delG (L295X) Null Basal-like
Bx15c WT GPM (HD) n.d. n.a.
Bx33c WT GPM (HD) n.d. n.a.
CAMA-1 WT 274G4C (D92H) Positive Luminal
EVSA-T WT 951del4 (T319X) n.d. n.a.
MDA-MB-415 WT 407G4A (C136Y) Positive Luminal
MDA-MB-453 WT 919G4A (E307K) Positive Luminal
MDA-MB-468 WT IVS4+1G4T (A72fsX5) Null Basal-like
ZR75-1 WT 323T4G (L108R) Positive Luminal
BT-20 WT WT Positive Basal-like
BT-474 WT WT Positive Luminal
BT-483 WT WT Positive Luminal
DU-4475 WT WT Positive n.a.
Hs578T WT WT Positive Basal-like
MCF-7 WT WT Positive Luminal
MDA-MB-134VI WT WT Positive Luminal
MDA-MB-157 WT WT Positive Basal-like
MDA-MB-175VII WT WT Positive Luminal
MDA-MB-231 WT WT Positive Basal-like
MDA-MB-361 WT WT Positive Luminal
MDA-MB-435S WT WT Positive Basal-like
SK-BR-3 WT WT Positive Luminal
SUM-159PT WT WT Positive Basal-like
T-47D WT WT Positive Luminal
UACC-812 WT WT Positive Luminal
UACC-893 WT WT Positive n.a.
ZR75-30 WT WT Positive Luminal
All mutations are relative to the +1 adenine nucleotide of the ATG start codon, with the amino acid change given
in parentheses. GPM, gross PTEN mutation; HD, homozygous deletion; CNI, DNA copy number increase; n.d., not
done; n.a., not available.
aFor cell line samples, BRCA1 mutational status is taken from ref. 19. bBreast cancer subtype is taken from ref. 20. cXenograft.







































in breast cancer and other types of carcinoma in which such changes
were once thought to be rare.
METHODS
Human tumor samples and immunohistochemistry. All tumor specimens
were studied after approval by the Lund University Hospital ethics committee
and Columbia University Institutional Review Board. Tissue microarrays
containing formalin-fixed paraffin-embedded tissues in replicates from 425
individuals diagnosed with stage II invasive breast cancer but without a signi-
ficant family history of breast or ovarian cancer were subjected to IHC staining
for CK5/14. CK5/14 IHC was performed and scored into CK5/14-positive
(defining basal-like status) and CK5/14-negative groups as described17. Some of
these individuals were evaluated for PTEN protein expression by IHC on
whole-mount, formalin-fixed, paraffin-embedded tissue sections, and the
tumors were scored as PTEN-positive (PTENIHC-positive) or PTEN-loss
(PTENIHC-loss) relative to normal epithelial, endothelial and/or stromal cells
in each tissue section as described15. Tumors with undetectable PTEN immu-
nostaining in contrast to adjacent normal cells were scored as PTEN-null
(PTENIHC-null). We analyzed 297 tumors for both PTEN and CK5/14. Thirty-
four breast tumors from carriers of germline BRCA1 mutations were obtained
for PTEN IHC and genetic analyses. PTEN IHC was performed and scored for
these tumors as above, with the exception that the primary antibody to PTEN
was monoclonal (138G6, Cell Signaling Technology; dilution, 1:200; incuba-
tion, 2 h), and the Dako EnVision Plus system was used for signal detection.
Cell lines and xenografts. Breast cancer cell lines were obtained from the
American Type Culture Collection and S. Ethier and were cultured according to
standard recommendations. The MX-1 (also known as Bx11), Bx15 and Bx33
breast cancer xenografts have been described21. PTEN protein blotting was
performed as described14.
BRCA1 promoter hypermethylation. BRCA1 promoter region methylation
was analyzed by using a PSQ HS 96 pyrosequencing system according to
manufacturer protocols (Biotage). DNA was isolated with a Wizard Genomic
DNA purification kit (Promega) and bisulfate-modified with a EZ DNA
Methylation kit (Zymo Research). We designed an assay containing two CpG
island regions with internal controls for bisulfite treatment (nucleotide posi-
tions are relative to the +1 adenine of the ATG translational start codon on the
annotated Ensembl v36 BRCA1 genomic sequence):
BRCA1 region 1, 1291 to 1267 (containing five
CpGs); and region 2, 1332 to1310 (four CpGs).






T-3¢. In all runs, CpGenome Universal Methylated
DNA (Chemicon) was analyzed as a positive
control, and CpGenome Universal Unmethylated
DNA and reactions with no DNA were used as
negative controls.
DNA sequencing. PTEN exons including intronic
boundaries were sequenced as described15. BRCA1
mutations were identified by standard techniques27.
aCGH. Experiments using the 32K BAC aCGH platform were performed
by using described methods28. A custom-designed HD-aCGH microarray
(Agilent) was also used as described29. In brief, this HD-aCGH microarray
contains 1,747 probes in replicates covering a region of B500 kb centered on
the PTEN locus at a mean spacing of 288 bp, and an additional B20,000
probes with wide genome coverage that are used for data normalization with
the popLowess algorithm29. Labeling and hybridization were performed
according to the manufacturer’s recommendations, and data were loaded into
BASE30 for analysis.
Two-color split-probe FISH. The following BACs were obtained from the
BACPAC Resource Center (Children’s Hospital Oakland Research Institute) or
Invitrogen, and DNA was prepared by standard techniques: RP11-1036I20,
RP11-57C13, RP11-210E13, RP11-79A15, RP11-765C10, CTD-2243A23,
RP11-959L24 and RP11-762G5. The RP11-1036I20, RP11-57C13, RP11-210E13
and RP11-79A15 probes 5¢ to PTEN were generated by nick translation
and labeled with spectrum orange dUTP; the RP11-765C10, CTD-2243A23,
RP11-959L24, RP11-762G5 probes 3¢ to PTEN were labeled with spectrum
green dUTP. Metaphase chromosome spreads were prepared, and FISH was
carried out by standard methods; hybridization signals were scored on at least
20 metaphase spreads.
Pten+/– mouse mammary tumors. The Pten+/– mouse model has been
described16. Mouse research was approved by the Columbia Animal Care
and Use Committee. Female mice developed mammary tumors at an average
age of 11 months. Thirteen tumors from 12 mice were collected, fixed in
formalin and embedded in paraffin. For IHC, primary antibodies D5/16 B4
(monoclonal antibody to CK5 or CK6 (anti-CK5/6); Covance) and AF64
(polyclonal anti-CK14; Covance) were used at 1:500 dilution and SC542
(polyclonal anti-ER; Santa Cruz) was used at 1:400 dilution after microwave
antigen retrieval in 0.01 M citrate buffer. D5/16 B4 was applied overnight
at 4 1C, whereas AF64 and SC542 were applied for 1 h at 22 1C.
A Vectastain kit (Vector Labs) was used to detect binding of the primary
antibody to its target antigen in accordance with the manufacturer’s recom-
mendation using 3,3¢-diaminobenzidine for visualization. Cytokeratin
immunostaining was scored as follows: 0, no staining; 1+, moderate staining;
2+, focally strong (o15% of cells); 3+, strong in 415% of cells. CK5/6/14-
positive was defined as 1+ (one case), 2+ (two cases) or 3+ (ten cases) for CK5/6
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Figure 5 Gross PTEN mutations in five
BRCA1-mutant breast tumor biopsies in vivo.
(a–e) Analysis of PTENIHC-null BRCA1-associated
breast tumors by HD-aCGH, revealing PTEN
homozygous deletions (a,e), macro-CNI (b) and
micro-CNIs (c,d). Probes and the PTEN locus are
plotted as in Figure 4a,b. Green bars indicate
neighboring genes.







































metaplastic tumor epithelial cell compartments. IHC staining of ER was
scored as follows: 0, o1% positive nuclei; 1+, 1–4% positive nuclei; 2+,
Z5% positive nuclei.
Statistical analyses. Correlations between variables in 2  2 tables were
assessed with Pearson’s w2 test, and tables with cells with fewer than five
observations were assessed with Fisher’s exact test (sum of small P values). Tests
were two-sided, and a P value ofo0.05 was considered significant. Assuming a
25% prior probability rate (the approximate rate of PTEN loss in breast
cancer), a one-sided P value for PTEN protein loss in BRCA1-associated
hereditary breast cancer was calculated as the probability of having 28 or more
PTENIHC-loss samples out of 34 cases with a binomial distribution.
Note: Supplementary information is available on the Nature Genetics website.
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